Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with the drugs Wall Street is betting everything on.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
BMY Reports Mixed Phase III Trial Results, Stock Down
Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Bristol Myers Squibb (BMY) reached $57.6 at the closing of the latest trading day, reflecting a -2.58% change compared to its last close.
Bristol Myers falls 3% despite positive cancer drug trial results
Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market's reaction to the announcement. The US drugmaker reported that its ACTION-1 Phase 3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for RYZ101 in patients with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?
Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity
Bristol-Myers Squibb is reiterated as a buy, offering attractive valuation and a high 4.23% dividend yield. BMY delivered a strong Q2 earnings triple-play, raising FY 2026 sales guidance and demonstrating robust growth in both legacy and new products. Despite looming patent cliffs and projected EPS declines post-2026, BMY benefits from high free cash flow and recent bullish EPS revisions.
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BMY or ARGX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
